EICHOR
● Completed
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
Condition: Recurrent Cervical Cancer · Metastatic Cervical Cancer · Sponsor: Akeso
About this study
This is a Phase 2, global, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic cervical carcinoma.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (25)
| Womens Cancer Research Foundation | Newport Beach, California, United States | — |
| Sylvester Comprehensive Cancer Center | Miami, Florida, United States | — |
| BRCR Medical Center | Plantation, Florida, United States | — |
| Augusta University Medical Center | Augusta, Georgia, United States | — |
| Illinois Cancer Specialists | Arlington Heights, Illinois, United States | — |
| Maryland Oncology Hematology (Plum Orchard) | Silver Spring, Maryland, United States | — |
| Monter Cancer Center | Lake Success, New York, United States | — |
| The Blavatnik Family - Chelsea Medical Center at Mount Sinai | New York, New York, United States | — |
| Oncology Hematology Care Inc | Cincinnati, Ohio, United States | — |
| Oklahoma Cancer Specialists and Research Institute, LLC | Tulsa, Oklahoma, United States | — |
| Chattanooga's Program In Women's Oncology | Chattanooga, Tennessee, United States | — |
| Tennessee Oncology - Centennial Clinic | Nashville, Tennessee, United States | — |
+ 13 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04380805